Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 5, 2016, Pages E577-E586

  Dekker, Joseph D ^a   Park, Daechan ^a,b   Shaffer, Arthur L ^c   Kohlhammer, Holger ^c   Deng, Wei ^a   Lee, Bum Kyu ^a   Ippolito, Gregory C ^a,b   Georgiou, George ^a,b   Iyer, Vishwanath R ^a   Staudt, Louis M ^c   Tucker, Haley O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b The University of Texas at Austin   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

DLBCL; FOXP1; Lymphoma

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXP1 PROTEIN, HUMAN; REPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL SURVIVAL; CELL TRANSFORMATION; CELL VIABILITY; COHORT ANALYSIS; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; LARGE CELL LYMPHOMA; LYMPHOCYTE SUBPOPULATION; LYMPHOMA CELL LINE; PLASMABLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; B LYMPHOCYTE; CELL DIFFERENTIATION; DIFFUSE LARGE B CELL LYMPHOMA; GENETIC TRANSCRIPTION; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE, TUMOR; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84956615779     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1524677113     Document Type: Article

References (54)

1. Howlader NNA, et al. (2013) SEER Cancer Statistics Review, 1975-2010 (National Cancer Institute, Bethesda, MD), Based on November 2012 SEER data submission. Available at seer.cancer.gov/archive/csr/1975-2010/. Accessed March 7, 2015.
2. Alizadeh AA, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503-511.
3. Rosenwald A, et al.; Lymphoma/Leukemia Molecular Profiling Project (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346(25):1937-1947.
4. Shaffer AL, 3rd, Young RM, Staudt LM (2012) Pathogenesis of human B cell lymphomas. Annu Rev Immunol 30:565-610.
5. Davis RE, Brown KD, Siebenlist U, Staudt LM (2001) Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194(12):1861-1874.
6. Lenz G, et al. (2008) Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319(5870):1676-1679.
7. Davis RE, et al. (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463(7277):88-92.
8. Ngo VN, et al. (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470(7332):115-119.
9. Banham AH, et al. (2005) Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 11(3):1065-1072.
10. Staudt LM, et al. (2007) Methods for identifying, diagnosing, and predicting survival of lymphomas. US Patent US20070105136 A1.
11. Shaffer AL, et al. (2001) Signatures of the immune response. Immunity 15(3):375-385.
12. Feng X, et al. (2010) Foxp1 is an essential transcriptional regulator for the generation of quiescent naive T cells during thymocyte development. Blood 115(3):510-518.
13. Gabut M, et al. (2011) An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming. Cell 147(1):132-146.
14. Shi C, et al. (2008) Down-regulation of the forkhead transcription factor Foxp1 is required for monocyte differentiation and macrophage function. Blood 112(12):4699-4711.
15. Wang B, Lin D, Li C, Tucker P (2003) Multiple domains define the expression and regulatory properties of Foxp1 forkhead transcriptional repressors. J Biol Chem 278(27):24259-24268.
16. Wang B, et al. (2004) Foxp1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation. Development 131(18):4477-4487.
17. Brown PJ, et al. (2008) Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. Blood 111(5):2816-2824.
18. Wlodarska I, et al. (2005) FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 19(8):1299-1305.
19. Sagaert X, et al. (2006) Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol 24(16):2490-2497.
20. Lenz G, et al. (2008) Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 105(36):13520-13525.
21. Ngo VN, et al. (2006) A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441(7089):106-110.
22. van Keimpema M, et al. (2014) FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells. Blood 124(23):3431-3440.
23. Bailey TL, et al. (2009) MEME SUITE: Tools for motif discovery and searching. Nucleic Acids Res 37(Web Server issue):W202-W208.
24. Care MA, et al. (2013) A microarray platform-independent classification tool for cell of origin class allows comparative analysis of gene expression in diffuse large B-cell lymphoma. PLoS One 8(2):e55895.
25. Shaffer AL, et al. (2002) Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 17(1):51-62.
26. Mandelbaum J, et al. (2010) BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 18(6):568-579.
27. Huang W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44-57.
28. Yang Y, et al. (2012) Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21(6):723-737.
29. Hirano T, Ishihara K, Hibi M (2000) Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19(21):2548-2556.
30. Kluk MJ, et al. (2012) Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One 7(4):e33813.
31. Ci W, et al. (2009) The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood 113(22):5536-5548.
32. Persengiev SP, Green MR (2003) The role of ATF/CREB family members in cell growth, survival and apoptosis. Apoptosis 8(3):225-228.
33. Liu DX, Qian D, Wang B, Yang JM, Lu Z (2011) p300-Dependent ATF5 acetylation is essential for Egr-1 gene activation and cell proliferation and survival. Mol Cell Biol 31(18):3906-3916.
34. Sagardoy A, et al. (2013) Downregulation of FOXP1 is required during germinal center B-cell function. Blood 121(21):4311-4320.
35. McLean CY, et al. (2010) GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol 28(5):495-501.
36. Li Z, et al. (2005) BCL-6 negatively regulates expression of the NF-kappaB1 p105/p50 subunit. J Immunol 174(1):205-214.
37. Sebastián E, et al. (2012) Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: Antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype. Am J Pathol 181(5):1879-1888.
38. Cox MC, et al. (2014) Clinicopathologic characterization of diffuse-large-B-cell lymphoma with an associated serum monoclonal IgM component. PLoS One 9(4):e93903.
39. Ruminy P, et al. (2011) The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma. Leukemia 25(4):681-688.
40. Tinguely M, et al. (2014) IRF8 is associated with germinal center B-cell-like type of diffuse large B-cell lymphoma and exceptionally involved in translocation t (14;16) (q32.33;q24.1). Leuk Lymphoma 55(1):136-142.
41. Carotta S, et al. (2014) The transcription factors IRF8 and PU. 1 negatively regulate plasma cell differentiation. J Exp Med 211(11):2169-2181.
42. Ingham RJ, et al. (2001) The Gab1 docking protein links the b cell antigen receptor to the phosphatidylinositol 3-kinase/Akt signaling pathway and to the SHP2 tyrosine phosphatase. J Biol Chem 276(15):12257-12265.
43. Tedoldi S, et al. (2006) Jaw1/LRMP, a germinal centre-associated marker for the immunohistological study of B-cell lymphomas. J Pathol 209(4):454-463.
44. Schmidlin H, et al. (2008) Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression. Blood 112(5):1804-1812.
45. Turner CA, Jr, Mack DH, Davis MM (1994) Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell 77(2):297-306.
46. Györy I, Fejér G, Ghosh N, Seto E, Wright KL (2003) Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines. J Immunol 170(6):3125-3133.
47. van Keimpema M, et al. (2015) The forkhead transcription factor FOXP1 represses human plasma cell differentiation. Blood 126(18):2098-2109.
48. Yoon HS, et al. (2012) ZBTB32 is an early repressor of the CIITA and MHC class II gene expression during B cell differentiation to plasma cells. J Immunol 189(5):2393-2403.
49. Morin RD, et al. (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476(7360):298-303.
50. Morin RD, et al. (2010) Somatic mutations altering EZH2(Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42(2):181-185.
51. Basso K, et al. (2010) Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. Blood 115(5):975-984.
52. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9(7):671-675.
53. Ippolito GC, et al. (2014) Dendritic cell fate is determined by BCL11A. Proc Natl Acad Sci USA 111(11):E998-E1006.
54. Hu H, et al. (2006) Foxp1 is an essential transcriptional regulator of B cell development. Nat Immunol 7(8):819-826.